NCT07284433 2026-03-12
QUADvance
AvenCell Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT05826535 2026-02-24
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2 Recruiting
NCT04855253 2026-01-15
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
Masonic Cancer Center, University of Minnesota
Phase 1/2 Suspended
NCT03676504 2024-07-29
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
University Hospital Heidelberg
Phase 1/2 Recruiting
NCT02926833 2024-03-06
ZUMA-6
Gilead Sciences
Phase 1/2 Completed
NCT04323657 2023-03-16
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
Phase 1/2 Completed
NCT03044743 2017-05-02
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Unknown
NCT02685670 2017-03-16
MatchCART
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Phase 1/2 Unknown